T1	p 305 314	and HIV-1
T2	p 328 378	from HIV-1-infected women to their male partners .
T3	p 430 493	3790 heterosexual HIV-1-serodiscordant couples participating in
T4	p 541 564	seven African countries
T5	p 593 625	hormonal contraceptive users and
T6	p 686 728	and HIV-1 transmission from women to men .
T7	p 935 947	1314 couples
T8	p 980 1007	partner was female ( median
T9	p 1113 1136	women who used hormonal
T10	p 1270 1282	2476 couples
T11	p 1315 1340	partner was male ( median
T12	p 1413 1440	from women to men were 2?61
T13	p 1476 1501	which women used hormonal
T14	p 1560 1565	which
T15	p 2119 2132	women with or
T16	p 2202 2233	Bill & Melinda Gates Foundation
T17	i 10 36	of hormonal contraceptives
T18	i 110 133	Hormonal contraceptives
T19	i 248 261	contraceptive
T20	i 573 615	injectable and oral hormonal contraceptive
T21	i 832 851	marginal structural
T22	i 886 899	contraceptive
T23	i 1137 1150	contraception
T24	i 1502 1515	contraception
T25	i 2038 2085	Non-hormonal or low-dose hormonal contraceptive
T26	i 2133 2140	at-risk
T27	i 2202 2222	Bill & Melinda Gates
T28	o 275 295	of HIV-1 acquisition
T29	o 528 537	incidence
T30	o 656 676	of HIV-1 acquisition
T31	o 761 781	HIV-1 seroconversion
T32	o 809 827	hazards regression
T33	o 841 851	structural
T34	o 1052 1078	rates of HIV-1 acquisition
T35	o 1385 1393	rates of
T36	o 1856 1876	of HIV-1 acquisition
T37	o 1881 1893	transmission
T38	o 1989 1999	protection
T39	o 2005 2012	condoms
T40	o 2031 2035	risk
T41	o 2187 2197	Health and